Author:
Di Forti Marta,Morgan Craig,Dazzan Paola,Pariante Carmine,Mondelli Valeria,Marques Tiago Reis,Handley Rowena,Luzi Sonija,Russo Manuela,Paparelli Alessandra,Butt Alexander,Stilo Simona A.,Wiffen Ben,Powell John,Murray Robin M.
Abstract
BackgroundPeople who use cannabis have an increased risk of psychosis an effect attributed to the active ingredient δ9-tetrahydrocannabinol (Δ9-THC). There has recently been concern over an increase in the concentration of Δ9-THC in the cannabis available in many countries.AimsTo investigate whether people with a first episode of psychosis were particularly likely to use high-potency cannabis.MethodWe collected information on cannabis use from 280 cases presenting with a first episode of psychosis to the South London & Maudsley National Health Service (NHS) Foundation Trust, and from 174 healthy controls recruited from the local population.ResultsThere was no significant difference between cases and controls in whether they had ever taken cannabis, or age at first use. However, those in the cases group were more likely to be current daily users (OR = 6.4) and to have smoked cannabis for more than 5 years (OR = 2.1). Among those who used cannabis, 78% of the cases group used high-potency cannabis (sinsemilla, ‘skunk’) compared with 37% of the control group (OR 6.8).ConclusionsThe finding that people with a first episode of psychosis had smoked higher-potency cannabis, for longer and with greater frequency, than a healthy control group is consistent with the hypothesis that Δ9-THC is the active ingredient increasing risk of psychosis. This has important public health implications, given the increased availability and use of high-potency cannabis.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
442 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献